07.31.18
Shire
2Q Revenues: $3.9 billion (+5%)
2Q Earnings: $616 million (+156%)
YTD Revenues: $7.7 billion (+5%)
YTD Earnings: $1.2 billion (+96%)
Comments: Immunology sales were $1.1 billion in the quarter, up 13% driven by Immunoglobulin therapies. Hematology sales were down 1% to $951.0 million. Neuroscience sales were up 9% to $693.7 million driven by Vyvanse and Adderall XR. Internal medicine revenues were up 61% to $232.9 million driven by Gattex and Natpara, up 77% and 88% respectively. Established product sales were down 36% to $218.5 million. In the quarter, Shire gained U.S. FDA approval for its plasma manufacturing facility near Covington, Georgia supporting its growing immunoglobulin portfolio.
2Q Revenues: $3.9 billion (+5%)
2Q Earnings: $616 million (+156%)
YTD Revenues: $7.7 billion (+5%)
YTD Earnings: $1.2 billion (+96%)
Comments: Immunology sales were $1.1 billion in the quarter, up 13% driven by Immunoglobulin therapies. Hematology sales were down 1% to $951.0 million. Neuroscience sales were up 9% to $693.7 million driven by Vyvanse and Adderall XR. Internal medicine revenues were up 61% to $232.9 million driven by Gattex and Natpara, up 77% and 88% respectively. Established product sales were down 36% to $218.5 million. In the quarter, Shire gained U.S. FDA approval for its plasma manufacturing facility near Covington, Georgia supporting its growing immunoglobulin portfolio.
